معرفی
Stefan Knapp is a Professor of Pharmaceutical Chemistry at Goethe University, leading research into small molecules targeting epigenetic mechanisms and cancer cell proliferation. His work emphasizes translational research, open science, and collaboration, exemplified by his role in managing the EUbOPEN consortium, which secured €65.8 million in funding. He focuses on developing therapies through partnerships with industry, prioritizing efficiency and transparency to accelerate drug discovery. Knapp's research interests include kinase inhibitors, molecular glues, and targeted protein degradation, with applications in oncology and neurodegenerative diseases.
His achievements include EMBO membership (2018) and pioneering open-science initiatives to share data and reagents rapidly. Knapp's lab employs cutting-edge methods like native Taylor dispersion-MS and fragment-based screening to identify novel therapeutic targets. Collaborative efforts span international networks, reflecting his belief in global teamwork for scientific advancement. Key projects include therapeutic targeting of NPM1c in AML and inhibition of LRRK2 in Parkinson's disease.
Grants and funding highlight his success in securing resources for transformative research, while his open-access approach aims to reduce redundant efforts and expedite medical breakthroughs. Knapp's interdisciplinary work bridges academia and industry, focusing on ethical and socially impactful science with direct clinical applications.
